{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:20:50Z","timestamp":1778498450406,"version":"3.51.4"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,12,12]],"date-time":"2005-12-12T00:00:00Z","timestamp":1134345600000},"content-version":"vor","delay-in-days":3267,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis & Rheumatism"],"published-print":{"date-parts":[[1997,1]]},"abstract":"Abstract<\/jats:title>Objective<\/jats:italic>. To evaluate the efficacy of long\u2010term treatment with cyclosporin A (CSA) in systemic lupus erythematosus (SLE).<\/jats:p>Methods<\/jats:italic>. Thirty patients with SLE whose condition was either poorly responsive or unresponsive to treatment with steroids and\/or cytotoxic drugs were enrolled in a prospective, nonrandomized study of CSA. Patients with hypertension or hypercreatinemia were excluded. Disease activity was evaluated according to the systemic lupus activity measure. Assessments were made prior to study entry and after 6, 12, 18, and 24 months.<\/jats:p>Results<\/jats:italic>. Twenty\u2010seven patients completed at least 24 months of treatment with CSA. The mean disease activity score significantly decreased after 6 months of therapy (P<\/jats:italic> < 0.01); this result was maintained throughout the study. A conspicuous steroid\u2010sparing effect was observed following administration of CSA (P<\/jats:italic> < 0.01). Side effects included hypertrichosis (63% of patients), paresthesias (23%), gastrointestinal symptoms (20%), gingival hyperplasia (17%), hypertension (10%), tremors (7%), and nephrotoxicity (13%). No significant changes in serum creatinine levels were observed.<\/jats:p>Conclusion<\/jats:italic>. CSA represents a helpful second\u2010choice treatment for patients with active SLE. Administration of CSA necessitates expert and careful followup of patients.<\/jats:p>","DOI":"10.1002\/art.1780400106","type":"journal-article","created":{"date-parts":[[2007,2,14]],"date-time":"2007-02-14T12:15:56Z","timestamp":1171455356000},"page":"27-35","source":"Crossref","is-referenced-by-count":87,"title":["Long\u2010term treatment of systemic lupus erythematosus with cyclosporin A"],"prefix":"10.1002","volume":"40","author":[{"given":"Domenico","family":"Caccavo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna P.","family":"Mitterhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni M.","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Afeltra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,12,12]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.16.5214"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6407112"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830150220"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-70607-3"},{"key":"e_1_2_1_6_2","volume-title":"Cyclosporin in Autoimmune Disease","author":"Bonomo L","year":"1990"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000168040"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198803173181103"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360113"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780371015"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507203330301"},{"key":"e_1_2_1_12_2","unstructured":"BonomoL Lagan\u00e0B CaccavoD GiorgiA:Cyclosporin in connective tissue autoimmune diseases The Second Congress on Immunointervention in Autoimmune Diseases: The Role of Sandimmun (Cyclosporin). Paris May 13\u201316 1991"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1990.tb02047.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/anr.1780320909"},{"key":"e_1_2_1_16_2","volume-title":"Cyclosporin in Autoimmune Disease","author":"Miescher PA","year":"1985"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370416"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(87)80057-4"},{"key":"e_1_2_1_19_2","first-page":"359","article-title":"Marked reduction of DNA antibody production and glomerulopathy in thymulin (FTS\u2010Zn) or cyclosporin\u2010A treated (NZB \u00d7 NZW)F1 mice","volume":"54","author":"Israel\u2010Biet DI","year":"1983","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780351116"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4049\/jimmunol.138.1.157","article-title":"CS\u2010A therapy in MRL\u2010lpr\/lpr mice: amelioration of immunopathology despite autoantibody production","volume":"138","author":"Mountz JD","year":"1987","journal-title":"J Immunol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370506"}],"container-title":["Arthritis & Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.1780400106","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.1780400106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T20:25:14Z","timestamp":1700771114000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.1780400106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,1]]}},"alternative-id":["10.1002\/art.1780400106"],"URL":"https:\/\/doi.org\/10.1002\/art.1780400106","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,1]]}}}